Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory EGFR -mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study.
Natasha B LeighlHiroaki AkamatsuSun Min LimYing ChengAnna R MinchomMelina E MarmarelisRachel E SanbornJames Chih-Hsin YangBaogang LiuThomas JohnBartomeu MassutiAlexander I SpiraSe-Hoon LeeJialei WangJuan LiCaigang LiuSilvia NovelloMasashi KondoMotohiro TamiyaErnesto KorbenfeldMor MoskovitzJi-Youn HanMariam AlexanderRohit JoshiEnriqueta Felip FontPei-Jye VoonPongwut DanchaivijitrPing-Chih HsuFelipe José Silva Melo CruzThomas WehlerLaurent GreillierEncarnação TeixeiraDanny NguyenJoshua K SabariAngel QinDariusz Mirosław KowalskiMehmet Ali Nahit ŞendurJohn XieDebopriya GhoshAli A AlhadabNahor Haddish-BerhanePamela L ClemensPatricia LorenziniRemy B VerheijenMohamed GamilJoshua M BaumlMahadi BaigAntonio Passaronull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Subcutaneous amivantamab-lazertinib demonstrated noninferiority to intravenous amivantamab-lazertinib, offering a consistent safety profile with reduced infusion-related reactions, increased convenience, and prolonged survival.